{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-211462","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.067106+00:00","generated_at":"2026-05-17T05:59:31.998821+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Benitec Biopharma FY2025 net loss $37.9M ($1.05/sh); BB-301 DSMB clears Cohort 2 enrollment","bullets":["Net loss $37.9M ($1.05/share) vs $22.4M ($1.22/share) in FY2024; total expenses $41.8M (up 86%).","R&D expense $18.3M (up 17%) on BB-301 clinical development; G&A $23.4M (up 235%) driven by stock-based comp $14.5M.","Cash and equivalents $97.7M (up from $50.9M) after equity offerings.","DSMB recommended continuation; Cohort 2 enrollment and interim Cohort 1 data both expected Q4 2025.","BB-301 Phase 1b/2a for OPMD with dysphagia; no revenue reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-211462","json":"https://secwatch.observer/filing/0001193125-25-211462.json","markdown":"https://secwatch.observer/filing/0001193125-25-211462.md","text":"https://secwatch.observer/filing/0001193125-25-211462.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312525211462/0001193125-25-211462-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312525211462/bntc-20250922.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:59:31.998821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}